Stocks · News reference
Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development CandidateOn October 15, 2026, Recursion announced that Sanofi has optioned the first development candidate from the two companies’
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Recursion Pharmaceuticals shares are trading after Needham reiterated its Buy rating on the stock and maintained a $8 price target.
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and a $10 million Sanofi milestone payment.
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight
The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.